Encephalitis caused by ganciclovir-resistant cytomegalovirus in a late-presenting person living with HIV, diffuse large B-cell lymphoma, and multiple opportunistic infections (EACS 2025) - Jul 16, 2025 - Abstract #eP.C016; Location: ePoster Exhibition; "He received BIC/FTC/TAF, azithromycin, ethambutol, cotrimoxazole, and chemotherapy for DLBCL (Figure 1A, 1B)...Ganciclovir and CMV-IVIG were initiated, followed by valganciclovir...Foscarnet was stopped due to septic shock. CMV resistance to ganciclovir and cidofovir was confirmed in November 2023, prompting the addition of letermovir...As of May 2025, the PLWH is clinically stable on DTG/3TC/ABC and letermovir prophylaxis. Ganciclovir-resistant CMV treatment is burdened by scarcity of second-choice medications, toxicity and uncertain CNS penetration. Letermovir might be an effective treatment alternative."
Cytomegalovirus Infection • Human Immunodeficiency Virus • Infectious Disease • Septic Shock • CD4
|
|
M. Vargović 1; L. Dragošević 2; J. Begovac 1,2; S. Židovec Lepej 3; I. Grgić 3; A. Atelj 1; G. Rinčić 4; M. Radmilović 5; L. Desnica 6; Z. Bošnjak 7,2; M. Santini 1,2
|